The importance of STAT5 in CML pathogenesis is further underscored by the fact that STAT5 expression increases during disease progression and that high STAT5 levels significantly decrease imatinib sensitivity [30, 31]. Here, STAT5A is linked to chronic myelogenous leukemia, BCR-ABL1 positive.